ResMed stockholders approve equity plan share increases; director exits board
At its November 19, 2025 annual meeting, ResMed stockholders approved amendments adding 2,400,000 shares to the 2009 Incentive Award Plan and 3,000,000 shares to the 2018 Employee Stock Purchase Plan, and elected eleven directors. Director Richard Sulpizio did not seek re-election, and the board reduced its size from twelve seats to eleven. The added shares increase the pool available for employee equity awards and stock purchases.
Key points
- 2009 Plan amendment: 2,400,000 additional shares, elimination of the fixed term, and authorization of incentive stock options
- ESPP amendment: 3,000,000 additional shares, elimination of the fixed term, and tax-qualified options under Section 423
- Say-on-pay advisory vote: 98,435,762 for, 11,004,916 against, 236,395 abstain
- KPMG LLP ratified as independent auditor for fiscal year ending June 30, 2026: 103,397,962 for, 10,908,581 against
The filing
Written by AI on Nov 8, 2026, 1:30 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 20, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.